DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Deena"


4 mentions found


☆ 3 traits Lux Capital's Deena Shakir looks for in early-stage startup founders as healthcare bets shrink
  + stars: | 2022-10-26 | by ( Rebecca Torrence | ) www.businessinsider.com   time to read: +5 min
Lux Capital has backed multiple first-time founders this year even as their investment pace slows. In early-stage investments, Lux Capital's Deena Shakir said founders' characters are paramount. Of those 13 founders, Lux Capital has backed four, making it the most-represented venture-capital firm on the list. Here are the top three traits Shakir said she's looking for right now in the founders that Lux Capital backs, in no particular order:1. Founder-market fitWhen examining a startup, Shakir said she has to first ask the question of why the founder is starting this particular company.
☆ Eisai, Biogen say Alzheimer's drug succeeds in slowing cognitive decline
  + stars: | 2022-09-27 | by ( Deena Beasley Julie Steenhuysen | Deena Beasley | Julie Steenhuysen | ) www.reuters.com   time to read: +5 min
Shares of Biogen and Eisai were halted, but shares of Eli Lilly & Co , which is also developing an Alzheimer's drug, were up 6.7% in after hours trade. Aduhelm was the first new Alzheimer's drug approved in 20 years after a long list of high-profile failures for the industry. Symptomatic brain swelling was seen in 2.8% of those in the lecanemab group and none of the placebo group, they said. Aduhelm's approval was a rare bright spot for Alzheimer's patients, but critics have called for more evidence that amyloid-targeting drugs are worth the cost. Other plaque-targeting antibodies in late-stage development for Alzheimer's patients include Roche Holding AG's (ROG.S) gantenerumab and Eli Lilly's donanemab.
☆ Alzheimer's drug study yields positive results, say makers Eisai and Biogen
  + stars: | 2022-09-27 | by ( Deena Beasley Julie Steenhuysen Rocky Swift | Deena Beasley | Julie Steenhuysen | ) www.reuters.com   time to read: +6 min
Globally, the figure could reach 139 million by 2050 without an effective treatment, Alzheimer's Disease International said. Aduhelm was the first new Alzheimer's drug approved in 20 years after a long list of high-profile failures for the industry. read morePatient advocacy groups hailed the news of positive lecanemab trial results. Micro hemorrhages in the brain occurred at a rate of 17% in the lecanemab group, and 8.7% in the placebo group. Aduhelm's approval was a rare bright spot for Alzheimer's patients, but critics have called for more evidence that amyloid-targeting drugs are worth the cost.
☆ Illumina's Grail expands use of cancer detection test with life insurer deal
  + stars: | 2022-09-20 | by ( Deena Beasley | ) www.reuters.com   time to read: +3 min
REUTERS/Mike Blake/File PhotoSept 20 (Reuters) - Cancer detection test maker Grail, acquired by Illumina Inc (ILMN.O) last year despite ongoing antitrust challenges, on Tuesday said it would expand use of its flagship Galleri test through a new agreement with life insurer John Hancock, a division of Manulife Financial (MFC.TO). The test, designed to detect more than 50 types of cancer before symptoms appear, looks at the DNA in a patient's blood to determine whether any come from cancer cells. Data have shown that, across the 50 cancer types, including early-stage to late-stage, the Galleri test correctly identified the presence of cancer in 51.5% of cases. read moreJohn Hancock said it is the first life insurance carrier to offer, under its wellness program, policyholder access to Grail's early cancer detection test. The U.S. Federal Trade Commission filed a lawsuit in March 2021 to stop the acquisition on the basis that it would slow innovation for cancer detection tests.
<< prev 2 next >>
Total: 4